Advertisement

Topics

Latest "The European Federation of Biotechnology" News Stories

19:13 EDT 21st September 2018 | BioPortfolio

Here are the most relevant search results for "The European Federation of Biotechnology" found in our extensive news archives from over 250 global news sources.

More Information about The European Federation of Biotechnology on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about The European Federation of Biotechnology for you to read. Along with our medical data and news we also list The European Federation of Biotechnology Clinical Trials, which are updated daily. BioPortfolio also has a large database of The European Federation of Biotechnology Companies for you to search.

Showing "European Federation Biotechnology" News Articles 1–25 of 10,000+

Friday 21st September 2018

European biotech companies enter IPO prep course


Ichor's Auctus Biologics Closes Quick $1.5MM

Auctus Biologics, Inc., a new portfolio company of Ichor Therapeutics, Inc., announced today the closure of $1.5MM in seed funding. The company will develop RPtag, a hyper-stable antibody mimetic scaffold published earlier th

Human medicines European public assessment report (EPAR): Prialt, ziconotide, Revision: 21, Authorised


STAT Plus: A European health insurer sues AstraZeneca over a patent maneuver

Patient advocates object to "evergreening" a drug patent to keep making money. Now an insurer is suing a drug maker over the practice.

New micro-platform improves understanding of cancer cells

A new low-cost, cell culture platform technique may provide insight for more effective cancer treatment, according to the researchers who developed it... The post

Shire Receives Approval of FIRAZYR (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan

Shire (LSE:SHP,NASDAQ:SHPG) the leading global biotechnology company focused on rare diseases, announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted manufacturing and marketing authorisation for FIRAZYR (icatibant injection), for the acute treatment of hereditary angioedema (HAE) attacks in adult patients with HAE. As quoted in the press release: HAE is a … C...

CHMP recommends EU approval for subcutaneous formulation of RoActemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis

Roche announced today that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the subcutaneous (SC) formulation of RoActemra® (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients one year of age and older.

Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA

Tetraphase Pharmaceuticals (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that the European Commission (EC) has adopted the Decision granting marketing authorisation for XERAVA (eravacycline) for injection for the treatment of complicated intra-abdominal infectio...

Human medicines European public assessment report (EPAR): Hulio, adalimumab, Revision: 0, Authorised

Going its own Way, European Regulators Reject Sarepta's Exondys 51 for DMD http://dlvr.it/Qkx4g1 pic.twitter.com/BBUxaeQ5R4

Going its own Way, European Regulators Reject Sarepta's Exondys 51 for DMD http://dlvr.it/Qkx4g1  pic.twitter.com/BBUxaeQ5R4

CoreLink Surgical Announces the launch of Articulating Expandable Posterior Lumbar System – FLXfit®15

CoreLink Surgical today announces the expanded commercial launch for the FLXfit®15 articulating-expandable intervertebral body fusion device. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005378/en/ Up to 15° of Controlled and Continuous Lordotic Exp

Together with @MedImmune, we’re unlocking new pathways in respiratory and exploring advancements in biotechnology to expand our toolkit of drug modalities. Learn how we’re doing this from @MariaBelvisi4, VP and Head, RIA Innovative Medicines: http://

Together with @MedImmune, we’re unlocking new pathways in respiratory and exploring advancements in biotechnology to expand our toolkit of drug modalities. Learn how we’re doing this from @MariaBelvisi4, VP and Head, RIA Innovative Medicines: http://bit.ly/2DiAiUf . pic.twitter.com/wqvkFdUuLH

Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma

-Approval Triggers Milestone Payment to Seattle Genetics of $10 Million- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval

Takeda lung cancer drug gets European panel nod https://reut.rs/2DtdxNM 

Takeda lung cancer drug gets European panel nod https://reut.rs/2DtdxNM 

Human medicines European public assessment report (EPAR): Viekirax, ombitasvir / paritaprevir / ritonavir, Revision: 15, Authorised

Remedy Plan Therapeutics Named Winner of MTC’s Inaugural Start-Up Pitch Contest at Bio+Tech18

The Maryland Tech Council (MTC) concluded its Bio+Tech18 Conference yesterday in Baltimore with the announcement of

Smart pills could ‘dumb down’ medical care

Research suggest that the use of smart pills should be only after carefully evaluating their clinical efficacy against standard of care drugs... The post Smart pills could ‘dumb down’ medical care appeared first on European Pharmaceutical Review.

Mylan & Biocon: CHMP Issues Positive Opinion Recommending Approval Of Fulphila

CANONSBURG (dpa-AFX) - Mylan N.V. (MYL) and Biocon Ltd. announced the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval...

Lilly migraine drug wins European panel thumbs-up https://reut.rs/2Ns8dhX 

Lilly migraine drug wins European panel thumbs-up https://reut.rs/2Ns8dhX 

Spark Therapeutics Announces Positive CHMP Opinion for One-time Gene Therapy LUXTURNA® (voretigene neparvovec) in the European Union

LUXTURNA would be first gene therapy for a genetic disease approved in both U.S. and EU LUXTURNA would be first and only gene therapy approved in EU to treat patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells, a condition leading to total blindness in most patients Positive opinion based o...

Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib

– Opinion Based on Pivotal Phase 2 ALTA Trial, in which ALUNBRIG Demonstrated an Objective Response Rate of 56% and Longest Reported Median Progression-Free Survival of 16.7 months in the Post-Crizotinib Setting – Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medi...

California Life Sciences Association Announces Winner of “Giants of Science” Life Sciences Grant Competition

Los Altos High School Named Recipient of $20,000 Grant to Bolster Science Program Giants of Science is a program hosted by CLSA, CLSI and KNBR to Support Bay Area STEM Education California Life Sciences Association (CLSA), the trade association representing California’s life sciences industry, and

Spark/Novartis eye gene therapy nears EU market – but at what price?

Spark Therapeutics’ and Novartis Luxturna gene therapy for a rare inherited eye disease has been okayed by European regulators, paving the way for an EU licence in the coming months. A marketing authorisation from the European Commission is usuall...

Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim

Novartis International AG / Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety...

Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe

Novartis International AG / Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Children and adolescents with multiple sclerosi...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks